Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure

• Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD).

• The primary efficacy endpoint of this trial was the percent change from baseline in the modified Eczema Area and Severity Index (mEASI) score at week four.

• The trial achieved its primary endpoint with statistical significance, which corresponded to a 74.4% reduction in mEASI score from baseline in ATI-1777 arm compared to a 41.4% reduction in vehicle arm.

• In addition, positive trends in favor of ATI-1777 were observed in key secondary efficacy endpoints, such as improvement in itch, percent of mEASI-50 responders, IGA responder analysis, and reduction in BSA impacted by the disease.

• ATI-1777 was generally well-tolerated. No serious adverse events were reported. One treatment-related adverse event, application site pruritus, was reported in one subject in the ATI-1777 arm.

• Final trial results will be submitted for publication in a peer-reviewed scientific journal.

• Management will host a conference call and webcast today at 8:00 AM ET.

• Price Action: ACRS shares are up 2.9% at $23.02 during the premarket session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients

• Histogen Secures .5M Via Direct Equity Offering

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.